‘Our Gold Standard qualification acknowledges the leadership of Blue Cross and Blue Shield of NEW YORK president and CEO Brad Wilson and the commitment of the complete organization to cancer avoidance, which starts with building the fitness of its workers and family and reaches strengthening the wellbeing of its people and the broader community,’ stated Weldon. ‘It’s an honor for our firm to be regarded for our leadership in helping our workers to live healthful and much longer lives,’ stated Wilson. ‘I am especially pleased with the employees who function diligently to build up award-winning applications and initiatives to greatly help prevent tumor among our workers. To earn Gold Regular accreditation, a organization must offer applications and foster a lifestyle that may lower cancer risk.It’s not a viable business design in the long-term. Drug companies can’t afford it and neither can we as a culture. The problem is especially acute for sufferers with rare diseases. In the U.S., a rare disease is defined by the Orphan Drug Act of 1983 as one that afflicts fewer than 200,000 people nationwide. There are about 7,000 different rare diseases, which affect about 30 million Americans together, according to the Institute of Medicine. Significantly less than 5 % of these diseases have therapies, and the therapies which exist come at reduced price because drug makers need to recoup their costs.